Psychiatrist Dr Tiago Reis Marques discusses what new research findings on ketamine mean for treatment-resistant mental conditions such as major depressive disorder.
Atai Life Sciences and Introspect Digital Therapeutics will be testing a novel, digital therapeutic approach for patients using ketamine for treatment resistant depression.
Braxia Scientific will be carrying out a landmark clinical trial investigating multiple-dose psilocybin for treatment-resistant depression.
A systematic review of medical research has shown that ketamine and esketamine show no adverse cognitive effects in treatment-resistant depression.
Salvinorin A, derived from the plant Salvia divinorum, is to be researched as a treatment for mental health conditions.
Wesana Health is to undertake a functional animal study to determine the effect of psilocybin treatment on Traumatic Brain Injury (TBI), and anxiety and depression.
A team of researchers has identified novel mechanistic insights on how ketamine exerts an anti-depression effect, raising the hope of finding new treatment options for the...
